 |
  
Biotech Jobs, Learning Resources, Career Tools
|
|
| ||||||||||||||||||||||||||||||
|  |  Genzyme licenses technology from UCLA and JNJ's Remicade Gets Expanded EU ApprovalPress Release October 10, 2005 City of Industry, CA --(www.FinancialNewsUSA.com)-- 10/10/2005 - Biotechnology industry news provided by Financial News USA (OTC: FNWU) Cambridge, Mass.-based Genzyme (NASDAQ:GENZ) said Thursday that it wi ll license from the University of California at Los Angeles rights to its discovery of gene mutations believed connected to drug resistance to Gleevec. The drug is a Novartis AG first-line therapy for patients who suffer from chronic myeloid leukemia. Abbott (NYSE:ABT) will announce its financial results for the third quarter ended Sept. 30, 2005, on Wednesday, Oct. 19. On that day, Abbott will conduct a conference call with the investment community and the media to review the company's third-quarter financial performance. A live webcast of the conference call will begin at 9 a.m., Central time, and will be accessible through Abbott's Investor Relations Web site at http://www.abbottinvestor.com . An archived edition of the call will be available after noon Central time. Johnson & Johnson's (NYSE:JNJ) Centocor unit and partner Schering-Plough Corp. said Thursday that European regulators expanded the approval of their Remicade drug to include its use against a common form of psoriasis. Remicade was already approved in Europe to treat rheumatoid arthritis, Crohn's disease, ankylosing spodylitis and arthritis that is associated with psoriasis. Like these diseases, the psoriasis skin disorder is caused by a malfunctioning immune system that starts to attack healthy cells. U.S. BioDefense (OTCBB: UBDE) is pleased to announce recently that it has received its first stem cell line as a part of an agreement with the University of British Columbia. The company will begin evaluation of the neural crest stem cell line before beginning production of a commercial line which will be available for research use by Universities and other biotech companies. About Financial News USA Financial News USA is a Next Generation Financial Communications firm focused on the distribution of market moving news. Financial News USA has developed leading edge e-publishing tools including programming proprietary RSS feeds and enabling open source press release publishing across its network. Financial News USA has been aggressively expanding its news distribution network by targeting direct feeds to financial news and data providers such as FinancialContent, Yahoo (NASDAQ: YHOO), among others. Financial News USA offers a free news feed available online (www.financialnewsusa.com) to websites and financial services looking for content and for individual investors looking to stay informed on the financial markets. Financial News USA and its affiliates charge each client cash for news distribution and may take an equity position in the companies mentioned herein, please visit the disclaimer at www.financialnewsusa.com Contact Information: Financial News USA Tel: (626) 961-8041 Email: info@financialnewsusa.com
About hireBio
::
Copyright ::
Privacy
:: Legal
:: Contact |
 |
|
 |
Print
This Page